1, Xinhua Medical
As of the end of the second quarter, the company has contractual liabilities of ?1.869? billion yuan, with plenty of orders in hand. Strong main business, pharmaceutical equipment and medical equipment business rapid growth. According to the company's plan, to determine the medical equipment, pharmaceutical equipment as the two core business, focusing on breakthrough hemodialysis, radiotherapy, in vitro diagnostics, biopharmaceutical equipment field. 22H1?Pharmaceutical equipment business revenue increased by 60% year-on-year, the medical equipment business by the impact of the epidemic to achieve a steady growth in revenue.
In the company has the advantage of the industry in the field of infection control equipment, laboratory equipment, surgical instruments, etc., intensive cultivation to stabilize the leading position in the industry, the contract amount is abundant. Among them, the infection control product line domestic market share of ?70% or more, the scale of the domestic first; radiation therapy equipment domestic production of the most complete varieties, the number of domestic installed capacity of the leading, the scale of the domestic first.
2, Dongfulong
Dongfulong as a domestic pharmaceutical equipment leader to lead the development, committed to the intelligent pharmaceutical plant deliverer, to the equipment consumables as well as the engineering field of the whole direction of the development of the overall solution. Dongfulong thick accumulation, bioengineering and consumables into the discharge stage, 2022?year?H1?contract liabilities?3.9?billion yuan, an increase of?41% year-on-year, highlighting the company's performance growth potential is strong. The rapid development of the domestic biopharmaceutical industry opens up the domestic market space for biopharmaceutical equipment, biopharmaceutical equipment compared to chemical equipment categories, chain length, industry cycle attributes significantly weakened, the localization of alternative will be strong.